LeonaBio Appoints Callori, Holles and Silverman to Strengthen Clinical Pipeline Strategy
LeonaBio appointed Fred Callori, Natalie Holles and Peter B. Silverman to its Board effective May 5, 2026, replacing retiring director John Fluke Jr. after his decade-long tenure. The additions bring extensive oncology and neurology drug development, corporate strategy and capital markets expertise to support advancement of LeonaBio’s clinical-stage pipeline.
1. Board Reorganization and Appointments
LeonaBio appointed Fred Callori, Natalie Holles and Peter B. Silverman to its Board effective May 5, 2026. The company expanded its governance team ahead of advancing multiple oncology and neurology candidates in its clinical-stage pipeline.
2. Director Profiles and Expertise
Fred Callori brings capital markets and life sciences acceleration experience from Perceptive Advisors and Xontogeny; Natalie Holles has led biotech teams as CEO at Aura Biosciences and Third Harmonic Bio; Peter B. Silverman offers operational and intellectual property leadership from Merus N.V. and Kirkland & Ellis.
3. Strategic Objectives
The new board members’ combined drug development, corporate strategy, operational execution and capital raising experience aligns with LeonaBio’s goal to advance lead candidates and enhance shareholder value. Their appointments aim to bolster program prioritization, partnership readiness and future financing activities.
4. Retirement of John Fluke Jr.
John Fluke Jr., who served on LeonaBio’s Board since 2014, retired on May 4, 2026. His decade-long counsel helped shape early discovery programs and establish corporate governance foundations.